In a report released on May 8, Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report), with a price target of $73.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jonathan Chang’s rating is based on Zai Lab’s promising pipeline and strategic advancements. Despite a slight revenue miss in the first quarter of 2025, attributed to seasonal factors and inventory adjustments, the company expects a rebound in patient volumes and sequential growth for the rest of the year.
Furthermore, Zai Lab has made significant progress in its pipeline, including the initiation of a global Phase I/II study for ZL-1310 and submissions for Tivdak and repotrectinib to the Chinese NMPA. The company is also anticipating key clinical updates, such as the Phase I data for ZL-1310 in small-cell lung cancer and results from the Phase III FORTITUDE-101 study for bemarituzumab. These developments, along with a broad pipeline of commercial and development-stage assets, underpin Chang’s positive outlook on Zai Lab.